Pelthos Therapeutics Inc. (PTHS): Total Liabilities
$91.52M
As of 2025-12-31
$138.86M
As of 2026-06-30
+189.8%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $91.52M | n/m | 2026-03-19, Balance as of period end |
| 2024-12-31 | $4.08M | -37.6% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $6.54M | +73.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $3.76M | n/a | 2024-04-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
Compare PTHS, RLAY, LENZ, LCTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗